Published in Cancer Weekly, July 29th, 1996
David C. Bupp, Neoprobe, said, "They will now begin a statutory review procedure for our RIGScan CR49 product, which is designed to locate cancerous tissue during surgery for patients with metastatic cancer of the colon or rectum (colorectal)." Bupp continued, "With an average seven to eight month approval period by the European regulatory authorities, we look forward to a possible product launch for RIGScan CR49 in Europe as early as the first quarter of 1997."
The company has planned to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.